Heterocyclic Compounds

Matches 51 - 100 out of 9,413	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/051721A1	TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS The present disclosure provides certain tetracyclic derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
WO/2024/051784A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
WO/2024/052512A1	HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...
WO/2024/054603A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain-containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating dise...
WO/2024/053650A1	COMPOUND HAVING INHIBITORY ACTIVITY AGAINST DIACYLGLYCEROL KINASE α AND/OR ζ, AND PHARMACEUTICAL USE THEREOF The present invention addresses the problem of providing a compound having inhibitory activity against DGK α and/or ζ.　As a result of diligent study, the inventors of the present invention found, as a substance that can solve the abo...
WO/2024/050640A1	4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)PYRIDO[4,3-D]PYRIMIDINES AND USE THEREOF AS KRAS INHIBITORS The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-asso...
WO/2024/054926A1	KRAS G12D INHIBITORS The present disclosure relates to KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/050708A1	BLUE LIGHT EMITTING GUEST MATERIAL AND USE The present invention relates to the field of organic display, and in particular to a blue light emitting guest material and a preparation method therefor, and an organic light emitting device. The blue light emitting guest material is a...
WO/2024/046471A1	USP1 INHIBITOR The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
WO/2024/046420A1	FUSED BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...
WO/2024/050370A1	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
WO/2024/046406A1	ALKYLIDENE CARBAMATE AS KRAS INHIBITORS Provided herein are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing suc...
WO/2024/046370A1	HETEROCYCLIC COMPOUNDS AS KRAS INHIBITORS, AND PREPARATION AND THERAPEUTIC USE THEREOF The present invention relates to compounds of formula (I) and formula (II), or pharmaceutically acceptable salts, prodrugs, tautomers, or stereoisomers and solvates thereof. Said compounds can be used for the treatment of cancers and inf...
WO/2024/048519A1	PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...
WO/2024/045066A1	ALKYLIDENE CARBAMATE AS KRAS INHIBITORS Provided are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compo...
WO/2024/042361A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2024/041643A1	FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF The present disclosure relates to a fused tricyclic compound, a preparation method therefor, and medical use thereof. Specifically, the present disclosure relates to a fused tricyclic compound represented by general formula (I), a prepar...
WO/2024/042316A1	PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin doma...
WO/2024/041589A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND USE THEREOF Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as represented b...
WO/2024/044344A1	PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/041183A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS The present application relates to an organic compound, an organic electroluminescent device, and an electronic apparatus. The organic compound of the present application has a structure represented by formula (1). By applying the organi...
WO/2023/073641A9	ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS This invention provides for compounds of the formula: (I) wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and/or prevention of a parasitic infesta...
WO/2024/042494A1	SUBSTITUTED PYRROLOTRIAZINES The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...
WO/2024/041621A1	K-RAS MUTANT PROTEIN INHIBITORS The invention provides K-Ras mutant protein inhibitors of formula (Ⅰ), a composition containing the same and the use thereof.
WO/2024/041573A1	FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D or other KRAS mutants, and their uses.
WO/2024/041606A1	COMPOUND WITH ANTI-KRAS MUTANT TUMOR ACTIVITY The present invention provides a compound represented by formula (I) for use as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and use of the compound in treating a cancer.
WO/2024/040190A1	INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
WO/2024/038356A1	SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1'-heteroaryl and 1,1'-biheteroaryl compounds, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infections in a pati...
WO/2024/040109A2	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/037459A1	AMIDE-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF Provided are a series of amide-containing heterocyclic derivatives and the use thereof, and specifically provided are compounds represented by formula (III) and pharmaceutically acceptable salts thereof.
WO/2024/032598A1	TGF-β INHIBITOR COMPOUND AND USE THEREOF The present application relates to a TGF-β inhibitor compound and the use thereof. Specifically, disclosed in the present application is a compound as represented by formula (I), or an isotope-labeled compound thereof, or an optical iso...
WO/2024/036097A1	HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS AND ISOTOPOLOGUES THEREOF Provided herein are heteroaromatic macrocyclic ether compounds and isotopologues thereof, or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, and methods of treating, preventing or man...
WO/2024/036270A1	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/033277A1	NEW HETEROCYCLIC COMPOUNDS The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...
WO/2024/032529A1	PROTEIN DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...
WO/2024/032589A1	TGF-β INHIBITOR COMPOUND AND USE THEREOF Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...
WO/2024/032673A1	PDE4B INHIBITOR AND USE THEREOF A compound represented by formula I, stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing same, and the use thereof as a PDE4B inhibitor in the preparation of a drug for treatment of rela...
WO/2024/035627A1	HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
WO/2024/032702A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.
WO/2024/034591A1	HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN To provide a compound useful as an active ingredient of a pharmaceutical composition for treating cancer, in particular, pancreatic cancer.　The present inventors examined compounds useful as an active ingredient of a pharmaceutical com...
WO/2024/032782A1	VACCINE ADJUVANTS AND USES THEREOF Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...
WO/2024/027695A1	COMPOUNDS AS HER2 INHIBITORS A class of compounds as HER2 inhibitors. Specifically, the present invention relates to compounds as shown in general formula (1), general formula (2) and general formula (3), a preparation method therefor, and the use of the compounds o...
WO/2024/031089A1	SARS-COV2 MAIN PROTEASE INHIBITORS The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
WO/2024/030647A1	COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2024/028411A1	COMBINATION THERAPY OF CDK7 INHIBITORS WITH OTHER ANTI-CANCER THERAPIES The present disclosure relates to combinations of cyclin-dependent kinase 7 (CDK7) inhibitors and other therapeutic treatments, in particular other anti-cancer agents, and uses of such combination(s) in the treatment of cancers.
WO/2024/030633A1	COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2024/028273A1	NOVEL CRYSTALLINE FORMS OF (S)-7-OXA-2-AZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID [7-(3,6-DIHYDRO-2H-PYRAN-4-YL)-4-METHOXY-THIAZOLO[4,5-C]PYRIDIN-2-YL]-AMIDE AND CO-CRYSTAL FORMS THEREOF The invention relates to novel crystalline forms of (S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyri din-2- yl]-amide, processes for their preparation, medicaments and pharma...
WO/2024/022362A1	FUSED RING COMPOUND WITH SULFUR-CONTAINING SUBSTITUENT, PREPARATION METHOD, INSECTICIDE COMPOSITION, AND USE The present invention belongs to the field of agricultural insecticides and particularly relates to a fused ring compound with a sulfur-containing substituent, a preparation method, an insecticide composition, and use. Compared with the ...
WO/2024/022471A1	KRAS INHIBITOR COMPOUND The present invention provides a KRAS inhibitor compound and a use thereof, and specifically discloses a heterocyclic compound as shown in formula (I-1) or formula (I-2), a pharmaceutically acceptable salt, a stereoisomer, a deuterated d...
WO/2024/022244A1	HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY The present application relates to a heterocyclic compound having biological activity represented by formula (I), a preparation method therefor and a pharmaceutical composition thereof, and further relates to an use of such a compound an...

Matches 51 - 100 out of 9,413	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >